Recruiting

Cancer Therapy-related Cardiotoxicity

Sponsor:

Mayo Clinic

Code:

NCT06353191

Conditions

Hematopoietic and Lymphatic System Neoplasm

Malignant Solid Neoplasm

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Non-Interventional Study

Study Details

Brief summary:

This study evaluates why some cancer patients but not others experience changes in heart function following treatment with chemotherapy.

Conditions

Hematopoietic and Lymphatic System Neoplasm

Malignant Solid Neoplasm

Study ID

NCT06353191

Start date

May 3, 2019

Status verified date

Aug, 2026

Completion date

Dec 31, 2031

Anticipated

Primary completion date

Dec 31, 2031

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • 18 years of age or older
  • Treated for any malignancy with any type of chemotherapy including oral, parenteral therapy and immunotherapy
  • One of the following:

  • Diagnosed with cardiotoxicity defined as; cardiomyopathy, symptomatic heart failure, asymptomatic reduced systolic function, acute coronary syndrome, myocardial infarction, critical limb ischemia, cardiac arrhythmias or myocarditis possibly related to prior cancer treatment
  • Completed chemotherapy with no cardiotoxicity at least two years post treatment
  • Patients with cancer who will be initiating systemic therapy with potentially cardiotoxic medications. This will include chemotherapy, immunotherapy, targeted therapy that have been associated with cardiac toxicity
  • An understanding of the protocol and its requirements, risks, and discomforts
  • The ability and willingness to sign an informed consent

Exclusion Criteria:

\- Inability on the part of the patient to understand the informed consent or be compliant with the protocol

Study Design

Enrollment

693 participants

Anticipated

Interventions and Outcome Measures

Arms

Observational

Patients undergo blood sample collection and have their medical records reviewed on study. Patients may also optionally undergo ECG on study.

Interventions

Non-Interventional Study

Non-interventional study

Primary outcome measure

  • Collection of biospecimens from patients who developed cardiac toxicity (CRCT) or who are at high risk for developing CRCT [ Time Frame: Baseline ]

Central Contacts and Locations

Central contacts

Clinical Trials Referral Office

855-776-0015mayocliniccancerstudies@mayo.edu

Locations

Mayo Clinic in Arizona

Recruiting

Scottsdale, Arizona, United States, 85259

Contacts

Clinical Trials Referral Office

855-776-0015mayocliniccancerstudies@mayo.edu

Myrah Manuel

480-574-3157Manuel.Myrah@mayo.edu

Principal Investigator:

Lida A. Mina, MD

Mayo Clinic in Florida

Recruiting

Jacksonville, Florida, United States, 32224-9980

Contacts

Clinical Trials Referral Office

855-776-0015mayocliniccancerstudies@mayo.edu

Pamela Williamson

904-953-4694Williamson.Pamela@mayo.edu

Principal Investigator:

Nadine Norton, PhD

Moffitt Cancer Center

Recruiting

Tampa, Florida, United States, 33612

Contacts

Aixa Soyano, MD

813-745-8268aixa.soyano@Moffitt.org

Principal Investigator:

Aixa Soyano, MD

More Information

Sponsor

Mayo Clinic

Last update posted

Aug 18, 2026

Last verified

Aug, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Mayo Clinic on 2026-08-18.